A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03441555. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
An open-label, dose-escalation study to assess the safety and pharmacokinetics (PK), to determine the dose limiting toxicity (DLT) and the recommended Phase 2 dose (RPTD), and to assess the preliminary efficacy of alvocidib with venetoclax when co-administered in participants with relapsed or refractory (R/R) acute myeloid leukemia (AML).
Study identification
- NCT ID
- NCT03441555
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 30, 2018 (Actual)
- Primary completion
- Jan 25, 2021 (Actual)
- Completion
- Jan 25, 2021 (Actual)
- Last update posted
- Feb 1, 2022
2018 – 2021
United States locations
- U.S. sites
- 9
- U.S. states
- 6
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Cancer Center /ID# 170844 | Los Angeles | California | 90033 | — |
| UC Irvine /ID# 201093 | Orange | California | 92868 | — |
| University of California, Davis Comprehensive Cancer Center /ID# 170799 | Sacramento | California | 95817 | — |
| Sylvester Comprehensive Cancer /ID# 170761 | Miami | Florida | 33136-1002 | — |
| Indiana Blood & Marrow Transpl /ID# 170793 | Indianapolis | Indiana | 46237 | — |
| NYU Langone Medical Center /ID# 201559 | New York | New York | 10016-6402 | — |
| Weill Cornell Medical College /ID# 170800 | New York | New York | 10021 | — |
| Duke University Medical Center /ID# 170842 | Durham | North Carolina | 27710-3000 | — |
| University of Pittsburgh Medic /ID# 170790 | Pittsburgh | Pennsylvania | 15261 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03441555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 1, 2022 · Synced Nov 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.